Tohoku University. Research Profiles

  • Top
  • Life Sciences
  • Development and evaluation of various inhibitors and disinfectants for SARS-CoV-2

Development and evaluation of various inhibitors and disinfectants for SARS-CoV-2



Using the infectious SARS-CoV-2 (severe acute respiratory syndrome coronavirus-2), we are evaluating and developing new therapeutic drug candidates as well as evaluating disinfectants. Further analyses such as mechanism of action and resistance may be applicable. Other pathogens, including influenza virus and drug-resistant bacteria, will be examined upon request and discussion. Through joint and collaborative research with domestic and overseas pharmaceutical companies and related companies, we have experience of their clinical application including basic research.

Targeted Application(s)/Industry

We support development and evaluation of various inhibitors and disinfectants for variants of SARS-CoV-2 as well as wild type.


International Research Institute of Disaster Science

KODAMA Eiichi , Professor


Related Information

・ Hattori et al. A small compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nature Communications 12: Article number: 668, 2021
・ Biyania et al. Development of robust isothermal RNA amplification assay for lab-free testing of RNA viruses. Scientific Reports 11, Article number: 15997, 2021
・ Yamada et al. Genetic loci for lung function in Japanese adults with adjustment for exhaled nitric oxide levels as airway inflammation indicator. Communications Biology 4, Article number: 1288, 2021 doi:10.1038/s42003-021-02813-8
・ Morioka et al. Factors associated with prolonged psychological distress among nurses and physicians engaged in COVID-19 patient care in hospitals in Singapore and Japan. Frontiers in Psychiatry 13:781796, 2022 doi:10.3389/fpsyt.2022.781796
・ Iwamoto et al. Change in use of pediatric oral antibiotics in Japan: Pre and post AMR action plan. Pediatrics International 2022 doi:10.1111/ped.15197 in printing
・ Suzuki et al. Interferon lambda 3 in the early phase of coronavirus disease-19 can predict disease progression. European Journal of Clinical Investigation 2022 doi:10.1111/eci.13808 in printing